Market-Moving News for July 14th
Portfolio Pulse from Benzinga Newsdesk
Roivant Sciences is in talks with Roche for a $7 billion stomach disease drug deal. JPMorgan's Q2 investment banking revenue is up 11% to $1.5B, but total markets revenue is down 10% to $7B. Acadia Pharmaceuticals acquires ex-North American rights to Trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome for an upfront payment of $100M.
July 14, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JPMorgan's Q2 investment banking revenue is up 11% to $1.5B, but total markets revenue is down 10% to $7B.
While JPMorgan's investment banking revenue has increased, the decrease in total markets revenue could offset this positive impact, leading to a neutral impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Acadia Pharmaceuticals acquires ex-North American rights to Trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome for an upfront payment of $100M.
Acadia's acquisition of rights to Trofinetide and NNZ-2591 could potentially lead to new revenue streams, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Roivant Sciences is in discussions with Roche for a $7 billion deal for a stomach disease drug.
The potential $7 billion deal with Roche could significantly boost Roivant's revenues and profitability, which would likely lead to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100